Completed
Framing Messages for Smoking Cessation With Buproprion
What is being tested
Bupropion
+ Smoking Abstinence Program
DrugBehavioral
Who is being recruted
Mental Disorders+1
+ Tobacco Use Disorder
+ Substance-Related Disorders
From 18 to 70 Years
+12 Eligibility Criteria
How is the trial designed
Treatment Study
Interventional
Study Start: September 2000
Summary
Principal SponsorYale University
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: September 1, 2000
Actual date on which the first participant was enrolled.This is a randomized study of message framing in individuals beginning a smoking cessation program utilizing bupropion SR and brief counseling, videos, and pamphlets.
Official TitleFraming Messages for Smoking Cessation With Buproprion
Principal SponsorYale University
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
252 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.From 18 to 70 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Mental DisordersTobacco Use DisorderSubstance-Related DisordersChemically-Induced Disorders
Criteria
12 exclusion criteria prevent from participating
Pregnant or nursing women, or women of child-bearing potential who are not using an adequate method of contraception
Psychiatric illnesses requiring psychotropic medications (i.e., psychosis, major depression, mania), or the presence of suicidality or homocidality
Current use of nicotine replacement therapies (i.e., nicotine patch, gum, or lozenges, nasal spray, or inhaler), bupropion (Zyban, Wellbutrin), or marijuana or current participation in another smoking cessation treatment
Presence of unstable medical conditions (i.e., cardiac, hepatic, renal disease, diabetes mellitus) that would make a trial of bupropion SR hazardous
Show More Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
2 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Group I
Active ComparatorGain framed video and printed messages encouraging smoking abstinence with Bupropion.
Group II
Active ComparatorLoss framed video and printed messages encouraging smoking abstinence with Bupropion.
Study Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Suspended
Substance Abuse Treatment Unit
New Haven, United StatesOpen Substance Abuse Treatment Unit in Google MapsCompletedOne Study Center